Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors

ConclusionThis current study suggests that EGFR-TKIs is a better choice for patients with unresectable stage IIIEGFR-mutant adenocarcinoma. However, further randomized studies are required to validate the results.

Source: Thoracic Cancer - November 20, 2021 Category: Cancer & Oncology Authors: Sheng ‐Yuan Wang, Ching‐Han Lai, Chian‐Wei Chen, Szu‐Chun Yang, Chao‐Chun Chang, Chia‐Ying Lin, Yi‐Ting Yen, Yau‐Lin Tseng, Po‐Lan Su, Chien‐Chung Lin, Wu‐Chou Su Tags: ORIGINAL ARTICLE Source Type: research